Serina Therapeutics, Inc. (SER) Net margin 2017–2025
Serina Therapeutics, Inc. (SER) net profit margin by fiscal year — reported net income divided by reported revenue.
-14755.4%FY2025 · since FY2017: -468.7% → -14755.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -14755.4% | +5139.3 pp |
| FY2024 | -19894.6% | -20061.8 pp |
| FY2023 | 167.1% | +30937.7 pp |
| FY2022 | -30770.6% | -24746.3 pp |
| FY2021 | -6024.3% | -3014.6 pp |
| FY2020 | -3009.7% | -2306.3 pp |
| FY2019 | -703.4% | -166.0 pp |
| FY2018 | -537.4% | -68.7 pp |
| FY2017 | -468.7% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice